Patrick Darken

Triple Inhaled Therapy at Two Glucocorticoid Doses in Moderate-to-Very-Severe COPD

Klaus F. Rabe, Fernando J. Martinez, Gary T. Ferguson et al. · New England Journal of Medicine · 2020 · 635 citations · Full text

Triple therapy with budesonide/glycopyrrolate/formoterol fumarate with co-suspension delivery technology versus dual therapies in chronic obstructive pulmonary disease (KRONOS): a double-blind, parallel-group, multicentre, phase 3 randomised controlled trial

Gary T. Ferguson, Klaus F. Rabe, Fernando J. Martínez et al. · The Lancet Respiratory Medicine · 2018 · 388 citations

Translational Medicine, Pulmonary Care, Advanced Lung Disease +8

The Efficacy and Safety of Fluticasone Propionate (250 μg)/Salmeterol (50 μg) Combined in the Diskus Inhaler for the Treatment of COPD

Nicola A. Hanania, Patrick Darken, Donald H. Horstman et al. · CHEST Journal · 2003 · 327 citations

Pulmonary Care, Allergy, Advanced Lung Disease +7

Reduced All-Cause Mortality in the ETHOS Trial of Budesonide/Glycopyrrolate/Formoterol for Chronic Obstructive Pulmonary Disease. A Randomized, Double-Blind, Multicenter, Parallel-Group Study

Fernando J. Martínez, Klaus F. Rabe, Gary T. Ferguson et al. · American Journal of Respiratory and Critical Care Medicine · 2020 · 244 citations · Full text

Cardiovascular Safety of Salmeterol in COPDa

Gary T. Ferguson, Christian Funck‐Brentano, Tracy Fischer et al. · CHEST Journal · 2003 · 106 citations

Pulmonary Circulation, Cardiovascular Disease, Cardiovascular Safety +3